Document is current
Any future updates will be listed below
-
Authors
Ernst, Philipp https://orcid.org/0000-0001-5165-9874
Rinke, Jenny https://orcid.org/0009-0006-7791-6561
Franke, Georg-Nikolaus
Dicker, Frank
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Ernst, Thomas https://orcid.org/0000-0003-2147-489X
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
- License Information
-
More Information
Article History
Received: 11 June 2024
Revised: 20 June 2024
Accepted: 26 June 2024
First Online: 4 July 2024
Competing interests
: PE, JR, GNF, TE, and AH received support from Novartis through the European Treatment and Outcome Study (EUTOS) for CML. AH received research support from Novartis, BMS, Pfizer, Incyte, Enliven, and TERNS and is Editor-in-Chief of the journal LEUKEMIA. TH declares equity ownership. FD is employed by the MLL. GNF received fees and travel support from Novartis and served on scientific boards for Incyte. PE received fees for consulting services from Pfizer.
